S&P 500 › Sectors
Health Care
Stocks60
Average X-Ray Score50
Undervalued by fair value6
Market Compass outlookNeutral 51/100
All industriesHealth Care Equipment 16Life Sciences Tools & Services 9Biotechnology 8Pharmaceuticals 7Health Care Services 5Health Care Distributors 4Managed Health Care 4Health Care Supplies 3Health Care Facilities 2Health Care Technology 2
Health Care · ranked by X-Ray Score
| # | Company | Price | Today | X-Ray | Fair value | To fair value |
|---|---|---|---|---|---|---|
| 1 | INCY Incyte Corp | 113.07 | −0.18% | 81 | Not rated | – |
| 2 | RMD Resmed Inc | 238.97 | −1.35% | 73 | Fair | +25% |
| 3 | DXCM Dexcom Inc | 86.04 | −1.90% | 71 | Not rated | – |
| 4 | PODD Insulet Corp | 141.10 | +1.68% | 69 | Fair | +20% |
| 5 | ZTS Zoetis Inc. | 79.38 | +1.22% | 68 | Undervalued | +107% |
| 6 | IDXX Idexx Laboratories Inc | 560.36 | +2.41% | 67 | Overvalued | −23% |
| 7 | DVA Davita Inc. | 187.31 | −0.98% | 66 | Data under review | – |
| 8 | CI Cigna Group | 302.30 | +1.17% | 66 | Data under review | – |
| 9 | UHS Universal Health Services Inc | 185.10 | −1.21% | 66 | Data under review | – |
| 10 | VEEV Veeva Systems Inc | 310.36 | −0.85% | 65 | Fair | −23% |
| 11 | HCA HCA Healthcare, Inc. | 458.84 | −2.06% | 64 | Undervalued | +117% |
| 12 | STE STERIS plc | 222.66 | −0.74% | 64 | Fair | +7% |
| 13 | BSX Boston Scientific Corp | 44.39 | +0.57% | 63 | Fair | +9% |
| 14 | ELV Elevance Health, Inc. | 428.26 | −0.04% | 62 | Undervalued | +60% |
| 15 | ALGN Align Technology Inc | 147.31 | −1.36% | 61 | Fair | +27% |
| 16 | LLY ELI LILLY & Co | 1,257.03 | +0.43% | 61 | Overvalued | −31% |
| 17 | ISRG Intuitive Surgical Inc | 426.70 | −0.27% | 61 | Overvalued | −33% |
| 18 | UNH Unitedhealth Group Inc | 401.43 | −1.29% | 59 | Fair | +38% |
| 19 | BMY Bristol Myers Squibb Co | 59.75 | −1.35% | 59 | Fair | +12% |
| 20 | DGX Quest Diagnostics Inc | 235.00 | −1.74% | 57 | Fair | +5% |
| 21 | SYK Stryker Corp | 294.66 | +0.49% | 56 | Fair | −8% |
| 22 | VRTX Vertex Pharmaceuticals Inc / Ma | 499.74 | −1.77% | 55 | Fair | −4% |
| 23 | MCK Mckesson Corp | 1,004.84 | +0.62% | 55 | Overvalued | −35% |
| 24 | EW Edwards Lifesciences Corp | 86.60 | −1.70% | 55 | Overvalued | −35% |
| 25 | MDT Medtronic plc | 94.75 | −0.73% | 55 | Fair | −18% |
| 26 | ZBH Zimmer Biomet Holdings, Inc. | 94.98 | +0.64% | 53 | Fair | +5% |
| 27 | CAH Cardinal Health Inc | 254.06 | +0.14% | 52 | Data under review | – |
| 28 | CVS CVS HEALTH Corp | 92.36 | −0.24% | 52 | Fair | +22% |
| 29 | AMGN Amgen Inc | 432.49 | −0.35% | 51 | Fair | −13% |
| 30 | HUM Humana Inc | 413.16 | −4.41% | 51 | Fair | +21% |
| 31 | JNJ Johnson & Johnson | 255.56 | +0.90% | 50 | Fair | −16% |
| 32 | REGN Regeneron Pharmaceuticals, Inc. | 790.74 | −0.70% | 50 | Fair | +16% |
| 33 | MTD Mettler Toledo International Inc/ | 1,622.29 | −1.02% | 50 | Overvalued | −27% |
| 34 | GEHC GE HealthCare Technologies Inc. | 69.57 | −1.11% | 49 | Undervalued | +51% |
| 35 | SOLV Solventum Corp | 85.81 | −2.33% | 49 | Undervalued | +142% |
| 36 | COR Cencora, Inc. | 340.92 | −0.14% | 49 | Overvalued | −41% |
| 37 | BIIB Biogen Inc. | 232.65 | −1.15% | 47 | Fair | −0% |
| 38 | CNC Centene Corp | 69.16 | −1.91% | 46 | Data under review | – |
| 39 | LH Labcorp Holdings Inc. | 317.95 | −2.19% | 46 | Fair | −5% |
| 40 | COO Cooper Companies, Inc. | 57.94 | +0.94% | 46 | Fair | +4% |
| 41 | GILD Gilead Sciences, Inc. | 156.19 | −0.75% | 45 | Fair | +46% |
| 42 | WST West Pharmaceutical Services Inc | 384.02 | +0.26% | 44 | Overvalued | −44% |
| 43 | HSIC Henry Schein Inc | 86.38 | −0.70% | 42 | Fair | +9% |
| 44 | A Agilent Technologies, Inc. | 172.97 | −1.47% | 42 | Overvalued | −29% |
| 45 | IQV Iqvia Holdings Inc. | 266.90 | −1.53% | 42 | Overvalued | −25% |
| 46 | ABT Abbott Laboratories | 104.89 | +0.20% | 42 | Overvalued | −27% |
| 47 | ABBV AbbVie Inc. | 285.42 | +0.71% | 41 | Overvalued | −50% |
| 48 | TECH BIO-TECHNE Corp | 72.57 | +0.07% | 40 | Overvalued | −55% |
| 49 | BDX Becton Dickinson & Co | 191.75 | −1.04% | 39 | Overvalued | −39% |
| 50 | ILMN Illumina, Inc. | 262.54 | −2.01% | 39 | Data under review | – |
| 51 | TMO Thermo Fisher Scientific Inc. | 690.00 | −0.93% | 33 | Overvalued | −45% |
| 52 | MRK Merck & Co., Inc. | 145.95 | +0.52% | 32 | Overvalued | −64% |
| 53 | BAX Baxter International Inc | 25.28 | −1.86% | 29 | Not rated | – |
| 54 | DHR Danaher Corp | 229.04 | −1.06% | 28 | Overvalued | −49% |
| 55 | PFE Pfizer Inc | 29.58 | +0.48% | 27 | Overvalued | −47% |
| 56 | VTRS Viatris Inc | 18.66 | +2.41% | 26 | Undervalued | +97% |
| 57 | RVTY Revvity, Inc. | 152.64 | −1.34% | 24 | Overvalued | −63% |
| 58 | CRL Charles River Laboratories Interna... | 300.15 | −1.99% | 22 | Overvalued | −44% |
| 59 | WAT Waters Corp | 436.95 | −1.62% | 22 | Data under review | – |
| 60 | MRNA Moderna, Inc. | 218.01 | −7.82% | 13 | Not rated | – |
X-Ray Score combines valuation, growth, profitability, financial health and dividends, ranked within the sector. Educational only, not financial advice.